Biopharma VC Funding Fell in Q3, Scrip Reports

Biopharma venture capital investment fell in the third quarter, according to a new Scrip analysis, yet the same report projects that 2026 remains on track for overall growth.

That pairing defines the story. One weak quarter. One forecast that still points up. Investors pulled back between July and September, but the full-year trajectory, in Scrip's assessment, has not broken.

By Daniel Okafor

What happened in Q3?

Venture money flowing into biopharma companies declined in the third quarter. Scrip, the industry intelligence service that produced the analysis, describes the period as a slump. The report does not frame the drop as a collapse; it frames it as a pullback inside a year that still shows expansion.

This matters because quarterly venture numbers move markets and hiring plans. A down quarter can freeze late-stage rounds, delay IPO preparation, and push biotech founders toward partnerships instead of equity sales. The mechanism is simple: when funds write fewer checks, companies stretch runways and cut programs.

Why does 2026 still look strong?

Scrip's central claim is that the third-quarter decline does not derail 2026. The year remains on track for growth in biopharma venture investment, the report states.

That judgment implies the earlier quarters carried enough volume to absorb one soft period. It also implies that the pipeline of deals — the companies seeking money and the funds prepared to supply it — has not thinned. Scrip's read is that the underlying trend survives the quarterly noise.

What does a quarterly slump actually change?

Quarterly figures are the most volatile lens on venture activity. A single large round, closed or delayed, can swing a quarter's total by a wide margin. Third quarters also sit inside summer, when board calendars thin and closing schedules stretch.

So the practical reading of Scrip's report cuts two ways:

• Short term: less money moved into biopharma between July and September, which tightens conditions for companies raising now.
• Medium term: the annual forecast still points upward, which supports continued fundraising, deal formation and IPO planning into the rest of 2026.

For startup CFOs, the first point dominates. For limited partners weighing new biotech funds, the second point matters more.

Who feels a down quarter first?

Early-stage companies feel it least, because seed and Series A decisions rest on science and team rather than exit windows. Late-stage companies feel it most, because their valuations depend on comparable financings and public-market proxies. When a quarter slumps, the gap between what founders want and what funds will pay widens, and deals take longer to close.

Scrip's report does not single out a stage as the source of the decline. It reports the aggregate movement: less venture investment in Q3, growth still expected for the year.

What should readers watch next?

Two signals will settle whether Scrip's growth forecast holds. The first is the fourth-quarter data: a rebound would confirm the slump was seasonal noise rather than a turning point. The second is the composition of the deals that do close — whether money concentrates in a few large late-stage rounds or spreads across many smaller ones, since concentration makes quarterly totals swing harder.

For now, the baseline is Scrip's: Q3 was weak, 2026 still points up, and the next quarter's numbers will show which signal wins.